Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.

The pharmacogenomics journal - 1 Aug 2015

Arimany-Nardi C, Montraveta A, Lee-Vergés E, Puente X S, Koepsell H, Campo E, Colomer D, Pastor-Anglada M

Abstract excerpt

Bendamustine is used in the treatment of chronic lymphocytic leukemia (CLL). Routes for bendamustine entry into target cells are unknown. This study aimed at identifying transporter proteins implicated in bendamustine uptake. Our results showed that hOCT1 is a bendamustine transporter, as bendamustine could cis-inhibit the uptake of a canonical hOCT1 substrate, with a Ki in the micromolar range, consistent with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Exome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HEK293 Cells

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Membrane Transport Proteins

Share to Organic Anion Transporters

Share to Organic Cation Transport Proteins

Share to Organic Cation Transporter 1

Source

Identifiers

PMID: 25582574
DOI: 10.1038/tpj.2014.77

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.PMID 25582574Read ↗

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.Semantic proximity Read ↗

The human organic cation transporter OCT1 and its role as a target for drug responsesSemantic proximity Read ↗

Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.Semantic proximity Read ↗

A Membrane Transporter Determines the Spectrum of Activity of a Potent DNA-Targeted Hybrid Anticancer AgentSemantic proximity Read ↗

hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Semantic proximity Read ↗

OCTN1 Is a High-Affinity Carrier of Nucleoside AnaloguesSemantic proximity Read ↗

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.Semantic proximity Read ↗

Human Organic Cation Transporter 1 Is Expressed in Lymphoma Cells and Increases Susceptibility to Irinotecan and PaclitaxelSemantic proximity Read ↗

A membrane transporter determines the spectrum of activity of a potent platinum–acridine hybrid anticancer agentSemantic proximity Read ↗

Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.Semantic proximity Read ↗

Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.Semantic proximity Read ↗

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.